The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in a phase 1 trial

Publisher Website
Google Scholar
Abstract
The pharmacokinetics of CI-921 were studied after 65 infusions over a 20-fold dose range (13–270 mg/m2 per day) in 16 patients during a phase 1 trial. CI-921 was given by a 15 min infusion on three consecutive days.Plasma samples were collected after the first and third infusions, and urine, at 6 h intervals throughout the 3 days. CI-921 concentrations were measured by an HPLC method. Maximum plasma concentrations ranged from 3–86 μmol/l.The plasma concentration-time disposition curves were mainly biphasic over the 24-h postinfusion period. There was no significant difference by the paired t-test between the Cmax, AUC,CL, Vss, MRT, t1/2α, or t1/2β calculated for the first and third infusions. The means (range) of model-independent pharmacokinetic parameters were: CL, 158 (94–290) ml/h per kg; Vss, 319 (219–614) ml/kg; MRT, 2.1 (1.1–3.5) h; t1/2α, 0.5 (0.2–1.1) h; and t1/2β, 2.6 (1.1–5.0) h. There was a strong linear correlation between the dose and the AUC and Cmax,suggesting linear kinetics over this dose range. A very small amount (<1%) of the total dose was excreted as unchanged CI-921 in the urine, mostly in the 12-h postinfusion period.